Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.37 USD | -1.79% | -2.42% | -10.92% |
May. 10 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
May. 01 | RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept | MT |
Financials (USD)
Sales 2024 * | 1.88B | Sales 2025 * | 2.06B | Capitalization | 6.22B |
---|---|---|---|---|---|
Net income 2024 * | 345M | Net income 2025 * | 444M | EV / Sales 2024 * | 2.72 x |
Net cash position 2024 * | 1.12B | Net cash position 2025 * | 1.67B | EV / Sales 2025 * | 2.21 x |
P/E ratio 2024 * |
18.9
x | P/E ratio 2025 * |
14.6
x | Employees | 1,310 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.74% |
Latest transcript on Exelixis, Inc.
1 day | -1.79% | ||
1 week | -2.42% | ||
Current month | -8.91% | ||
1 month | -9.76% | ||
3 months | +5.69% | ||
6 months | +1.76% | ||
Current year | -10.92% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 00-01-31 | |
Director of Finance/CFO | 56 | 15-07-14 | |
Amy Peterson
CTO | Chief Tech/Sci/R&D Officer | 57 | 23-08-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Garber
BRD | Director/Board Member | 68 | 04-12-31 |
Director/Board Member | 68 | 04-01-31 | |
George Poste
BRD | Director/Board Member | 79 | 04-07-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.24% | 0 M€ | +12.39% | - | |
2.62% | 0 M€ | -2.17% | - | |
1.67% | 0 M€ | 0.00% | ||
1.59% | 0 M€ | +8.89% | ||
1.30% | 4 M€ | +20.15% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 21.37 | -1.79% | 1,687,956 |
24-05-09 | 21.76 | +0.79% | 1,420,956 |
24-05-08 | 21.59 | -2.53% | 2,209,905 |
24-05-07 | 22.15 | +1.14% | 2,595,680 |
24-05-06 | 21.9 | 0.00% | 2,158,487 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.92% | 6.22B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- EXEL Stock